Cooperative Agreement W81XWH2020052

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...

The U.S. Defense Health Agency awarded a $1,996,885 project grant under the Military Medical Research and Development program (CFDA 12.420) to Selsym Biotech Inc., a woman-owned small business. The funding supports the development of SYMCLOT, a synthetic platelet mimetic particle technology, to augment hemostasis for patients requiring extracorporeal support, such as those with battlefield injuries. Previous grants from the National Institutes of Health have also supported Selsym Biotech's...

This $181,772 project grant from the National Heart, Lung and Blood Institute will support research into coagulopathy in sepsis patients. The grantee, Beth Israel Deaconess Medical Center, will conduct an ancillary study using viscoelastic monitoring to examine the effects of randomly assigned fluid resuscitation strategies on coagulation parameters in sepsis patients. Specifically, the study aims to: 1) analyze how liberal versus restrictive fluid administration impacts coagulation measurements...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), aims to engineer hemostatic red blood cells that can adhere to collagen and fibrin at injury sites to help stop non-compressible hemorrhage. The $234,000 award to the University of Colorado-Denver will fund research to: 1) synthesize the engineered red blood cells, 2) test their ability to enhance clot formation and stability in...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $286,740 to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division. The grant aims to elucidate the mechanisms of complement activation in traumatic injury, a leading cause of death in the United States. The research program consists of three key objectives: 1) investigating...

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $295,963 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate platelet activities under hypoxic storage conditions for whole blood transfusion. The project aims to develop a modernized whole blood storage platform that reduces initial oxygen content and maintains an oxygen-managed environment during...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $772,940 to Fibroplate Inc. to conduct preclinical research on the efficacy and safety of its Fibrinoplate-S (FPS) technology for accelerating surgical wound healing in breast cancer patients undergoing radiation therapy. The two-year project aims to: 1) Demonstrate FPS's ability to promote surgical wound healing after radiotherapy in a mouse model of metastatic breast cancer,...

The Project Grant award R21HL172497, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel lab-on-a-particle platform to measure platelet function and advance the diagnosis of bleeding disorders. The $225,600 award, spanning September 2024 to May 2026, will enable the University of Colorado-Denver to design peptide-functionalized hydrogel microparticles that can evaluate key...

The University of Pittsburgh was awarded an $827,072 project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program to develop TRAUMACHEK, a field-deployable dielectric coagulometer for comprehensive hemostatic assessment in remote damage control resuscitation. The grant will support the University's work to investigate medical solutions for the battlefield by transforming trauma care through innovative research into remote...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The DNA Medicine Institute, Inc. to develop a rapid, 5-minute point-of-care test that can measure anti-Factor Xa activity and hemoglobin levels. This diagnostic tool is intended to guide emergency management for patients on direct oral anticoagulants, potentially enabling quicker delivery of life-saving interventions. The 2-year project,...